CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer

Oncogene

Volumn 32, Issue 18, 2013, Pages 2282-2291

  Xie, C ^a   Jiang, X H ^a,b   Zhang, J T ^a   Sun, T T ^a   Dong, J D ^a   Sanders, A J ^c   Diao, R Y ^a,d   Wang, Y ^a   Fok, K L ^a   Tsang, L L ^a   Yu, M K ^a   Zhang, X H ^a   Chung, Y W ^a   Ye, L ^c   Zhao, M Y ^a   Guo, J H ^a   Xiao, Z J ^a   Lan, H Y ^a   Ng, C F ^a   Lau, K M ^e   Cai, Z M ^d   Jiang, W G ^c   Chan, H C ^a,b   more..

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

CFTR; miR 193b; uPA

Indexed keywords

MICRORNA; MICRORNA 193B; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE; ENZYME ACTIVITY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; UPREGULATION;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICE; MICE, NUDE; MICRORNAS; MOLECULAR SEQUENCE DATA; PROSTATIC NEOPLASMS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877577459     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.251     Document Type: Article

References (41)

1. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256: 774-779.
2. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073.
3. Cuthbert AW. New horizons in the treatment of cystic fibrosis. Br J Pharmacol 2011; 163: 173-183.
4. Wiehe M, Arndt K. Cystic fibrosis: a systems review. AANA J 2010; 78: 246-251.
5. McWilliams RR, Rabe KG, Olswold C, De AM, Petersen GM. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 2005; 104: 388-394.
6. Neglia JP, FitzSimmons SC, Maisonneuve P, Schoni MH, Schoni-Affolter F, Corey M et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995; 332: 494-499.
7. McWilliams RR, Petersen GM, Rabe KG, Holtegaard LM, Lynch PJ, Bishop MD et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. Cancer 2010; 116: 203-209.
8. Warren N, Holmes JA, al-Jader L, West RR, Lewis DC, Padua RA. Frequency of carriers of cystic fibrosis gene among patients with myeloid malignancy and melanoma. BMJ 1991; 302: 760-761.
9. Abraham EH, Vos P, Kahn J, Grubman SA, Jefferson DM, Ding I et al. Cystic fibrosis hetero-and homozygosity is associated with inhibition of breast cancer growth. Nat Med 1996; 2: 593-596.
10. Padua RA, Warren N, Grimshaw D, Smith M, Lewis C, Whittaker J et al. The cystic fibrosis delta F508 gene mutation and cancer. Hum Mutat 1997; 10: 45-48.
11. Qiao D, Yi L, Hua L, Xu Z, Ding Y, Shi D et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene 5T allele may protect against prostate cancer: a case-control study in Chinese Han population. J Cyst Fibros 2008; 7: 210-214.
12. Li Y, Sun Z, Wu Y, Babovic-Vuksanovic D, Li Y, Cunningham JM et al. Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk. Lung Cancer 2010; 70: 14-21.
13. Ding S, Gong BD, Yu J, Gu J, Zhang HY, Shang ZB et al. Methylation profile of the promoter CpG islands of 14 'drug-resistance' genes in hepatocellular carcinoma. World J Gastroenterol 2004; 10: 3433-3440.
14. Moribe T, Iizuka N, Miura T, Kimura N, Tamatsukuri S, Ishitsuka H et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer 2009; 125: 388-397.
15. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther 2010; 9: 33-45.
16. Son JW, Kim YJ, Cho HM, Lee SY, Lee SM, Kang JK et al. Promoter hypermethylation of the CFTR gene and clinical/pathological features associated with non-small cell lung cancer. Respirology 2011; 16: 1203-1209.
17. McMahon B, Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008; 36: 184-194.
18. Malinowsky K, Bollner C, Hipp S, Berg D, Schmitt M, Becker KF. UPA and PAI-1 analysis from fixed tissues-new perspectives for a known set of predictive markers. Curr Med Chem 2010; 17: 4370-4377.
19. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
20. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
21. Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL et al. miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer 2010; 127: 1363-1372.
22. Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer 2010; 46: 2828-2836.
23. Chen J, Zhang X, Lentz C, bi-Daoud M, Pare GC, Yang X et al. miR-193b Regulates Mcl-1 in Melanoma. Am J Pathol 2011; 179: 2162-2168.
24. Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene 2009; 28: 3937-3948.
25. Hou CC, Wang W, Huang XR, Fu P, Chen TH, Sheikh-Hamad D et al. Ultrasoundmicrobubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 2005; 166: 761-771.
26. Singh AP, Chauhan SC, Andrianifahanana M, Moniaux N, Meza JL, Copin MC et al. MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms. Oncogene 2007; 26: 30-41.
27. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 2004; 64: 622-630.
28. Southey MC, Batten L, Andersen CR, McCredie MR, Giles GG, Dite G et al. CFTR deltaF508 carrier status, risk of breast cancer before the age of 40 and histological grading in a population-based case-control study. Int J Cancer 1998; 79: 487-489.
29. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
30. Cozzi PJ, Wang J, Delprado W, Madigan MC, Fairy S, Russell PJ et al. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 2006; 37: 1442-1451.
31. Kumano M, Miyake H, Muramaki M, Furukawa J, Takenaka A, Fujisawa M. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 2009; 27: 180-186.
32. Sen R, Smale ST. Selectivity of the NF-{kappa}B response. Cold Spring Harb Perspect Biol 2010; 2: a000257.
33. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651.
34. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010; 102: 639-644.
35. Boncoeur E, Roque T, Bonvin E, Saint-Criq V, Bonora M, Clement A et al. Cystic fibrosis transmembrane conductance regulator controls lung proteasomal degradation and nuclear factor-kappaB activity in conditions of oxidative stress. Am J Pathol 2008; 172: 1184-1194.
36. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101: 2598-2605.
37. Vij N, Mazur S, Zeitlin PL. CFTR is a negative regulator of NFkappaB mediated innate immune response. PLoS One 2009; 4: e4664.
38. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci 2006; 11: 1388-1413.
39. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. Cancer J Clin 2007; 57: 43-66.
40. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182-12187.
41. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31: 3406-3415.